drugset / Trial / NCT05983237
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
Timeline
- Start
- 2023-08-15
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Fluzoparib | Small molecule | 50 mg | Oral |
| Subject | Fluzoparib | Small molecule | 150 mg | Oral |
| Subject | Temozolomide | Small molecule | 50 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |